LFG
LRMR icon

Larson Financial Group’s Larimar Therapeutics LRMR Stock Holding History

Larson Financial Group’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-4
Closed -$13 – 3587
2025
Q3 		$13 Buy
+4
New +$15 ﹤0.01% 3402
2025
Q1 		– Sell
-120
Closed -$464 – 3156
2024
Q4 		$464 Buy
+120
New +$792 ﹤0.01% 2220

Other funds holding LRMR

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Larson Financial Group's LRMR Position: Q4 2025 in Review

Larson Financial Group sold out of Larimar Therapeutics (LRMR) in Q4 2025, closing a stake of 4 shares — an estimated $13 sold.

Larson Financial Group first reported a position in LRMR in Q4 2024 and held it in 2 quarters. The position peaked at $464 in Q4 2024. 136 funds tracked by Wall St. Rank hold LRMR as of Q4 2025.

  • Larson Financial Group reported no remaining Larimar Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Larson Financial Group sold 4 Larimar Therapeutics shares in Q4 2025, an estimated $13.
  • Larson Financial Group first reported a position in Larimar Therapeutics in Q4 2024 and held it in 2 quarters.
  • Larson Financial Group's Larimar Therapeutics position peaked at $464 in Q4 2024.
  • 136 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q4 2025.

Based on Larson Financial Group's 13F filing for Q4 2025, filed 6 Feb 2026.